Drug intelligence / Profile preview

dynorphin b

Development stage
Unknown
Modality
Peptides, Recombinant Proteins and Enzymes
01

Overview

**Dynorphin B** is an endogenous opioid peptide derived from the precursor protein prodynorphin via cleavage by proprotein convertase 2. It is one of three major dynorphin peptides (alongside dynorphin A and neoendorphin) found in the central nervous system, particularly in regions such as the hypothalamus, medulla, pons, midbrain, and spinal cord[4][5]. Dynorphin B has the highest affinity for the **kappa opioid receptor (KOR)**, where it acts primarily as an agonist, eliciting inhibitory effects on neurotransmission and analgesia, but is also known to bind with lower affinity to mu and delta opioid receptors[1][5]. It can also exert effects via non-opioid pathways, including activation of protein kinase D (PKD) and dynamin-related protein 1 (DRP1), leading to mitochondrial fragmentation and dysfunction in certain cell types and mediating gene transcription in cell nuclei, particularly for cardiac lineage-associated genes (GATA-4 and Nkx-2.5)[2][3]. Its actions influence mood disorders, addiction behaviors, analgesia, dysphoria, stress responses, and mitochondrial dynamics.

Other names
dynorphin Bdyn B
02

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on dynorphin b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dynorphin b.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call